<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Glucose on 0x000216</title><link>https://Nexus-Security.github.io/tags/glucose/</link><description>Recent content in Glucose on 0x000216</description><generator>Hugo -- gohugo.io</generator><language>en</language><lastBuildDate>Mon, 27 Feb 2023 14:26:24 +0000</lastBuildDate><atom:link href="https://Nexus-Security.github.io/tags/glucose/index.xml" rel="self" type="application/rss+xml"/><item><title>Fosun Trade Medical Devices introduces a dual-function blood glucose and uric acid tester called BUZUD</title><link>https://Nexus-Security.github.io/fosun-trade-medical-devices-introduces-a-dual-function-blood-glucose-and-uric-acid-tester-called-buzud/</link><pubDate>Mon, 27 Feb 2023 14:26:24 +0000</pubDate><guid>https://Nexus-Security.github.io/fosun-trade-medical-devices-introduces-a-dual-function-blood-glucose-and-uric-acid-tester-called-buzud/</guid><description>Source: BUZUD, Fosun Trade Medical Devices. This image showcases the Safe AQ UG Blood Glucose and Uric Acid Monitoring System from BUZUD, Fosun Trade Medical Devices. This system allows for convenient at-home testing of both uric acid and blood glucose levels.
BUZUD, Fosun Trade Medical Devices, a medical device company, has launched the Safe AQ UG Blood Glucose and Uric Acid Monitoring System. This innovative device allows users to measure both blood sugar and uric acid levels from the comfort of their homes with ease and a high degree of accuracy.</description></item><item><title>Abbott introduces the Freestyle Libre Pro System for glucose monitoring in India</title><link>https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/</link><pubDate>Mon, 19 Dec 2022 10:51:45 +0000</pubDate><guid>https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/</guid><description>Research from the Asia Diabetes Foundation (ADF) indicates a growing trend of type II diabetes among young adults in Asia. A collaborative study by the ADF and Merck, called the Joint Asia Diabetes Evaluation (JADE), revealed that 18% of participants from nine Asian countries and territories were diagnosed with diabetes before the age of 40. This condition is known as young-onset diabetes.
While pharmaceutical company Merck offers the drug Janumet XR for type II diabetes treatment, healthcare company Abbott takes a different approach.</description></item></channel></rss>